{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:47:38Z","timestamp":1772930858106,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4966,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1093\/annonc\/mdj995","type":"journal-article","created":{"date-parts":[[2006,5,15]],"date-time":"2006-05-15T13:27:50Z","timestamp":1147699670000},"page":"iv25-iv30","source":"Crossref","is-referenced-by-count":32,"special_numbering":"S4","title":["Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma"],"prefix":"10.1016","volume":"17","author":[{"given":"M.S.","family":"Hertzberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Crombie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Taper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.F.","family":"Bradstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdj995_bb0010","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1200\/JCO.1993.11.10.1846","article-title":"High dose chemotherapy and autologous stem-cell transplantation for aggressive non-Hodgkins\u2019s lymphoma","volume":"11","author":"Vose","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj995_bb0015","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomized trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdj995_bb0020","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdj995_bb0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.1989.7.2.179","article-title":"Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin\u2019s disease","volume":"7","author":"Jagannath","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj995_bb0030","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin\u2019s lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj995_bb0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj995_bb0040","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year old follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj995_bb0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bmt.1701985","article-title":"Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease","volume":"24","author":"McQuaker","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdj995_bb0050","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin\u2019s lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj995_bb0055","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin\u2019s lymphoma: an intention-to-treat analysis","volume":"96","author":"Keralramani","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj995_bb0060","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin\u2019s disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj995_bb0065","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab significantly increases the complete remission rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj995_bb0070","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/annonc\/mdg704","article-title":"Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin\u2019s lymphoma","volume":"14","author":"Vose","year":"2003","journal-title":"Ann Oncol"},{"issue":"Supp 4","key":"10.1093\/annonc\/mdj995_bb0075","first-page":"iv33","article-title":"Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation","author":"Moskowitz","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdj995_bb0080","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant registry","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj995_bb0085","first-page":"33","article-title":"Dose-intensive ifosfamide for the treatment of non-Hodgkin\u2019s lymphoma","volume":"23","author":"Vose","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdj995_bb0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2125.1991.tb03860.x","article-title":"The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients","volume":"31","author":"Lewis","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"Supp 4","key":"10.1093\/annonc\/mdj995_bb0095","first-page":"iv29","article-title":"Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention","author":"Lokiec","year":"2006","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419413689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419413689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/suppl_4\/iv25\/436480\/mdj995.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T08:22:49Z","timestamp":1582186969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419413689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":18,"alternative-id":["S0923753419413689"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdj995","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}